These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 22871196)

  • 41. Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.
    Krishna Kumar D; Shewade DG; Loriot MA; Beaune P; Balachander J; Sai Chandran BV; Adithan C
    Eur J Clin Pharmacol; 2014 Jan; 70(1):47-56. PubMed ID: 24019055
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients.
    Shahin MH; Khalifa SI; Gong Y; Hammad LN; Sallam MT; El Shafey M; Ali SS; Mohamed ME; Langaee T; Johnson JA
    Pharmacogenet Genomics; 2011 Mar; 21(3):130-5. PubMed ID: 21228733
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.
    Johnson JA; Gong L; Whirl-Carrillo M; Gage BF; Scott SA; Stein CM; Anderson JL; Kimmel SE; Lee MT; Pirmohamed M; Wadelius M; Klein TE; Altman RB;
    Clin Pharmacol Ther; 2011 Oct; 90(4):625-9. PubMed ID: 21900891
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans.
    Schelleman H; Chen J; Chen Z; Christie J; Newcomb CW; Brensinger CM; Price M; Whitehead AS; Kealey C; Thorn CF; Samaha FF; Kimmel SE
    Clin Pharmacol Ther; 2008 Sep; 84(3):332-9. PubMed ID: 18596683
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Warfarin pharmacogenetics.
    Limdi NA; Veenstra DL
    Pharmacotherapy; 2008 Sep; 28(9):1084-97. PubMed ID: 18752379
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms.
    Wypasek E; Branicka A; Awsiuk M; Sadowski J; Undas A
    Thromb Res; 2014 Sep; 134(3):604-9. PubMed ID: 25042728
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects.
    Nakamura K; Obayashi K; Araki T; Aomori T; Fujita Y; Okada Y; Kurabayashi M; Hasegawa A; Ohmori S; Nakamura T; Yamamoto K
    J Clin Pharm Ther; 2012 Aug; 37(4):481-5. PubMed ID: 22172097
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation.
    Cho HJ; On YK; Bang OY; Kim JW; Huh W; Ko JW; Kim JS; Lee SY
    Clin Ther; 2011 Oct; 33(10):1371-80. PubMed ID: 21981797
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Warfarin pharmacogenetics: to genotype or not to genotype, that is the question.
    Cavallari LH; Nutescu EA
    Clin Pharmacol Ther; 2014 Jul; 96(1):22-4. PubMed ID: 24942399
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
    Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
    Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E
    Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin.
    Fung E; Patsopoulos NA; Belknap SM; O'Rourke DJ; Robb JF; Anderson JL; Shworak NW; Moore JH
    Semin Thromb Hemost; 2012 Nov; 38(8):893-904. PubMed ID: 23041981
    [TBL] [Abstract][Full Text] [Related]  

  • 53. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.
    Biss TT; Avery PJ; Brandão LR; Chalmers EA; Williams MD; Grainger JD; Leathart JB; Hanley JP; Daly AK; Kamali F
    Blood; 2012 Jan; 119(3):868-73. PubMed ID: 22010099
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Anticoagulation with warfarin].
    Schinzel H; Nitschmann S
    Internist (Berl); 2009 Aug; 50(8):1026-8. PubMed ID: 19499193
    [No Abstract]   [Full Text] [Related]  

  • 55. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin.
    Vecsler M; Loebstein R; Almog S; Kurnik D; Goldman B; Halkin H; Gak E
    Thromb Haemost; 2006 Feb; 95(2):205-11. PubMed ID: 16493479
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Warfarin dosing and the promise of pharmacogenomics.
    Dumas TE; Hawke RL; Lee CR
    Curr Clin Pharmacol; 2007 Jan; 2(1):11-21. PubMed ID: 18690851
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry.
    Botton MR; Bandinelli E; Rohde LE; Amon LC; Hutz MH
    Br J Clin Pharmacol; 2011 Sep; 72(3):442-50. PubMed ID: 21320153
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.
    Tham LS; Goh BC; Nafziger A; Guo JY; Wang LZ; Soong R; Lee SC
    Clin Pharmacol Ther; 2006 Oct; 80(4):346-55. PubMed ID: 17015052
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.
    Takahashi H; Wilkinson GR; Nutescu EA; Morita T; Ritchie MD; Scordo MG; Pengo V; Barban M; Padrini R; Ieiri I; Otsubo K; Kashima T; Kimura S; Kijima S; Echizen H
    Pharmacogenet Genomics; 2006 Feb; 16(2):101-10. PubMed ID: 16424822
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
    Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
    Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.